Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients.
about
Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases.miR-155 Dysregulation and Therapeutic Intervention in Multiple Sclerosis.Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients
P2860
Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Natalizumab Therapy Modulates ...... ine Expression in MS Patients.
@ast
Natalizumab Therapy Modulates ...... ine Expression in MS Patients.
@en
type
label
Natalizumab Therapy Modulates ...... ine Expression in MS Patients.
@ast
Natalizumab Therapy Modulates ...... ine Expression in MS Patients.
@en
prefLabel
Natalizumab Therapy Modulates ...... ine Expression in MS Patients.
@ast
Natalizumab Therapy Modulates ...... ine Expression in MS Patients.
@en
P2093
P2860
P1433
P1476
Natalizumab Therapy Modulates ...... kine Expression in MS Patients
@en
P2093
Elisa Caggiu
Gian Pietro Sechi
Giannina Arru
Giordano Madeddu
Leonardo A Sechi
Magdalena Niegowska
Stefania Leoni
P2860
P304
P356
10.1371/JOURNAL.PONE.0157153
P407
P577
2016-06-16T00:00:00Z